Insulin Treatment of Fasting or Postprandial Glucose in Type 2 Diabetes. Does It Matter? The South Danish Diabetes Study (SDDS)

Henriksen, Jan Erik; Gram, Jeppe; Beck-Nielsen, Henning
June 2007
Diabetes;Jun2007 Supplement 1, Vol. 56, pA51
Academic Journal
Insulin treatment of fasting hyperglycaemia using bedtime NPH insulin is often used in Type 2 diabetes whereas treatment of postprandial hyperglycaemia has not gained much impact. This investigator driven, randomised, intention to treat (ITT), and treat to target study compared the effect of NHP insulin given at bedtime with insulin Aspart alone given before the 3 main meals during 2 yrs. Beside insulin all patients received double blinded treatment with placebo or metformin or rosiglitazone or both, giving a total of 8 subgroups (factorial design). Patients treated with NPH insulin adjusted insulin dose based on measured fasting glucose concentrations and patients treated with Aspart based on glucose measured 1 1/2 hours following the meals. In total 371 patients with type 2 diabetes for at least 2 years and not sufficiently controlled on oral antidiabetic treatment and/or insulin were included. Age 56.3 ± 8.4yr (mean ± SD), BMI 33.9 ± 5.7 kg/m2, baseline HbA1c 8.6 ± 1.2%. 311 patients completed the study but data analysis is based on 369 ITT subjects. Overall, following 2 years treatment, Hba1c was significantly lower in patients treated with Aspart as compared to NPH insulin (-0,41%, (-0.6 to -0.22, 95% CI), p<0.001). Moreover, metformin treatment was associated with a decrease in Hba1c as compared to placebo (-0.60%, (-0.79 to -0.41), p<0.001) as was rosiglitazone (-0.55%, (-0.74 to -0.36), p<0.001). In subgroup analysis after 2 years treatment HbA1c was 8.3±1.3% in the NPH alone group, 7.8±1.1% in the Aspart alone group and in the two triple therapy groups treated with either Aspart or NPH insulin together with both metformin and rosiglitazone 7.0±1.0 and 6.8±0.9% respectively. Body weight increased more using insulin Aspart than using NPH insulin (5.9 ± 6.1 vs 4.7 ± 5.7 kg, p<0.01) whereas metformin versus placebo was associated with a lower increase (4.1 ± 5.5 vs 6.6 ± 6.0 kg, p<0.001) and rosiglitazone versus placebo with a greater increase (6.6 ± 6.4 vs 4.1 ± 5.1 kg, p<0.001). Clinical congestive hearth failure did not occur more often in patients treated with rosiglitazone. In conclusion treatment with insulin Aspart alone at mealtime is associated with a lower HbA1c as compared to treatment with NHP insulin at bedtime. Further addition of metformin and/or rosiglitazone to insulin treatment decreases HbA1c by approximately 0.6% each. Optimal treatment of Type 2 diabetes patients is best obtained by triple therapy combining insulin with metformin and rosiglitazone.


Related Articles

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Twice-daily insulin regimens in management of severe diabetes. Oakley, Nigel; Mather, Hugh; Hadley, Lindsay; Lynch, Janice; Pilkington, Thomas // Journal of the Royal Society of Medicine;May1981, Vol. 74 Issue 5, p363 

    Diurnal glucose profiles have been compared in ten insulin dependent diabetics receiving, firstly, a twice-daily soluble insulin (SI): isophane insulin (NPHI) regimen containing a high proportion of SI (mean 73%O) and, secondly, Mixtard insulin (30% SI, 70% NPHI). For each patient the two...

  • Metformin Improved Glycemic Control in Patients with Type 1 Diabetes. Gottlieb, Peter A.; Ellis, Samuel L.; Lopez, Phillip; Gutin, Raymond; Garg, Satish K. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA574 

    The purpose of this study was to evaluate glycemic control in adult patients with type 1 diabetes prescribed to metformin therapy from January 2000 to December 2005. Secondary outcomes included weight, BMI, and insulin dose. This was a retrospective study with a computer matched control group in...

  • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard; Rønn, Birgitte Biilmann // Diabetes;Jun2004, Vol. 53 Issue 6, p1614 

    The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age...

  • Self-monitoring of blood glucose was not cost-effective in non-insulin- treated type 2 diabetes. Simon, J. // Evidence Based Medicine;Dec2008, Vol. 13 Issue 6, p171 

    Design: cost-effectiveness analysis of a randomised controlled trial with 1-year follow-up (Diabetes Glycaemic Education and Monitoring [DiGEM]. Setting: 48 general practices in the UK. Patients: 453 patients {mean age 66 y, 57% men} who had non-insulin-treated type 2 diabetes with haemoglobin...

  • Eli Lilly Throws New Insulin Into the 'Mix.'. Trecroci, D. // Diabetes Health;Jul2006, Vol. 15 Issue 7, p37 

    The article features the premixed insulin Humalog Mix50/50 launched by Eli Lilly and Co. Humalog is intended to give blood glucose control between meals. It also provides a higher percentage of rapid-acting insulin for diabetics who need additional insulin control during mealtimes.

  • Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. Lund, Søren Søgaard; Tarnow, Lise; Astrup, Anne Sofie; Hovind, Peter; Jacobsen, Peter Karl; Alibegovic, Amra Ciric; Parving, Ida; Pietraszek, Lotte; Frandsen, Merete; Rossing, Peter; Parving, Hans-Henrik; Vaag, Allan Arthur // PLoS Clinical Trials;Oct2008, Vol. 5 Issue 10, Special section p1 

    Background: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type- 2 diabetes. We investigated the effect of a one-year treatment...

  • Pubertal stage and hypoglycaemia counterregulation in type 1 diabetes. Ross, L. A.; Warren, R. E.; Kelnar, C. J. H.; Frier, B. M. // Archives of Disease in Childhood;Feb2005, Vol. 90 Issue 2, p190 

    Aims: To compare physiological and autonomic responses to acute hypoglycaemia in diabetic children in pre-, mid-, and post-pubertal stages of development. Methods: Twenty seven children (8 pre-pubertal, 7 mid-pubertal, 12 post-pubertal) with type 1 diabetes were studied. Hypoglycaemia was...

  • Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Bajaj, Mandeep; Suraamornkul, Swangit; Suraamornkul, Swangjit; Pratipanawatr, Thongchai; Hardies, Lou J.; Pratipanawatr, Wilailak; Glass, Leonard; Cersosimo, Eugenio; Miyazaki, Yoshinori; DeFronzo, Ralph A. // Diabetes;Jun2003, Vol. 52 Issue 6, p1364 

    The effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous glucose production (EGP), and hepatic fat content was studied in 14 type 2 diabetic patients (age 50 +/- 2 years, BMI 29.4 +/- 1.1 kg/m(2), HbA(1c) 7.8 +/- 0.4%). Hepatic fat content (magnetic resonance spectroscopy) and...

  • Neutrophil Function in Neonates Born to Gestational Diabetic Mothers. Mehta, Rajeev; Petrova, Anna // Journal of Perinatology;Mar2005, Vol. 25 Issue 3, p178 

    OBJECTIVE:: To examine neutrophil functional activity in the cord blood of term neonates born to gestational diabetic mothers, in association with the type of diabetes and the development of neonatal hypoglycemia. METHODS:: Neutrophil chemotaxis, random motility, and chemiluminescence was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics